CSL Ltd
Company Profile
Business description
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world’s second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
Contact
655 Elizabeth Street
MelbourneVIC3000
AUST: +61 393891911
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
29,904
CSL Ltd News & Analysis
stocks
Chart of the Week: Morningstar’s forecast for CSL’s future
personal-finance
4 income investing mistakes
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,190.20 | 7.50 | -0.08% |
CAC 40 | 7,966.95 | 71.01 | 0.90% |
DAX 40 | 24,113.62 | 232.90 | 0.98% |
Dow JONES (US) | 46,441.10 | 43.21 | 0.09% |
FTSE 100 | 9,446.43 | 96.00 | 1.03% |
HKSE | 26,855.56 | 232.68 | 0.87% |
NASDAQ | 22,755.16 | 95.15 | 0.42% |
Nikkei 225 | 44,783.24 | 232.39 | 0.52% |
NZX 50 Index | 13,423.64 | 10.35 | -0.08% |
S&P 500 | 6,711.20 | 22.74 | 0.34% |
S&P/ASX 200 | 8,899.60 | 6.20 | -0.07% |
SSE Composite Index | 3,882.78 | 20.25 | 0.52% |